Ancriviroc - Schering-Plough
Alternative Names: SCH-351125; SCH-C; Schering-CLatest Information Update: 20 Aug 2009
Price :
$50 *
At a glance
- Originator Schering-Plough
- Class Antiretrovirals; Cyclic N oxides; Piperidines; Pyridines
- Mechanism of Action CCR5 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 23 Feb 2004 Data presented at the 11th Conference on Retroviruses and Opportunistic Infections (CROI-2004) have been added to the pharmacokinetic and Viral infections therapeutic trials sections
- 18 Mar 2002 A study has been added to the Viral Infections therapeutic trials, adverse events and pharmacokinetics sections
- 19 Oct 2001 Phase-I clinical trials for HIV infections treatment in USA (PO)